Stay updated on Imsidolimab in Generalized Pustular Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page.

Latest updates to the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page
- CheckyesterdayChange DetectedThe updates appear limited to formatting, dates, and minor UI sections; no changes to core study details or eligibility criteria are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check8 days agoNo Change Detected
- Check30 days agoChange DetectedUpgrade to v3.2.0 with an inserted government operating status notice; previous version v3.1.0 removed.SummaryDifference4%

- Check37 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%

- Check44 days agoChange DetectedNew sponsor and study details added (Vanda Pharmaceuticals; a single-arm, multiple-dose study of imsidolimab for GPP with a detailed description and date references). The old sponsor/links from AnaptysBio, Inc. were removed.SummaryDifference5%

- Check51 days agoChange DetectedUpdated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.3%

- Check58 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3%

Stay in the know with updates to Imsidolimab in Generalized Pustular Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page.